Search peptides, terms, sources/
Repair and regeneration

GHK-Cu

Also known as: Copper peptide GHK · Copper Tripeptide-1 · Glycyl-L-Histidyl-L-Lysine-Copper

Copper-binding tripeptide studied for skin ageing and wound healing. Topical cosmetic use; no licensed injectable product in the UK.

UK status and evidence last reviewed .

UK status
Not licensed in the UKChecked

Evidence grade: best single recorded finding

How grading works

Best recorded finding: Limited evidence (level 2 of 4 on our scale)

This grades the evidence behind one recorded finding. It does not rate the compound.

3 findings at this grade. See all findings

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. GHK-Cu is recorded as not licensed in the UK (checked 14 August 2026).

Best study type
Human trials2 human trials of GHK-Cu alone · 1 combination trial (with 5-ALA) · 1 animal · 1 lab (in-vitro)

What is GHK-Cu?

GHK-Cu is a naturally occurring copper-binding tripeptide studied for skin ageing and wound healing. In the UK, topical products with cosmetic claims are regulated as cosmetics rather than medicines, no licensed injectable product exists, and the controlled human evidence concerns topical use only.

The peptide is glycyl-L-histidyl-L-lysine (GHK), here bound to copper. It has been studied for effects on collagen and extracellular-matrix turnover. Whether a product counts as a cosmetic or a medicine depends on its ingredients and the claims made for it. No controlled human safety or efficacy data for injected or other systemic use has been identified.

Class
Copper-binding tripeptide (metallopeptide complex)
Origin
Endogenous
UK status
Not licensed in the UK
Best study type
Human trials
Evidence last reviewed

How does GHK-Cu work?

GHK-Cu is a small natural peptide that holds a copper ion. It is described as acting on several pathways at once: changing how collagen is made and broken down, drawing repair cells to injuries, promoting new blood vessels and acting as an antioxidant. No single receptor has been confirmed.

The mechanism in more detail

GHK-Cu is a small peptide (glycine-histidine-lysine) that occurs naturally in the body, chelating a copper ion to form the active GHK-Cu complex; levels decline with age. Rather than acting through a single defined receptor, it has been described across a body of in-vitro, animal and human research as working through several overlapping pathways: modulating both the synthesis and controlled breakdown of collagen, elastin and other extracellular-matrix components, influencing the balance of matrix-remodelling enzymes and their natural inhibitors, attracting immune and endothelial cells to sites of injury, promoting new blood-vessel formation, and showing antioxidant and anti-inflammatory activity. No single confirmed cell-surface receptor for this activity has been established in the literature reviewed.

Separately, large-scale gene-expression studies from the peptide’s originating research group report that GHK can alter expression of several thousand human genes associated with tissue repair and inflammation, described by that group as shifting gene activity toward a pattern more typical of younger tissue. This is plausible mechanistic data, but it has not been independently replicated outside the originating research group, and should be read as laboratory-level gene-expression research rather than a demonstrated clinical mechanism.

It is worth noting, for clarity, that the “GH” in GHK-Cu refers to its glycine-histidine amino-acid sequence and has no connection to growth hormone; the name is coincidental, not indicative of growth-hormone-axis activity.

Almost all human clinical evidence for GHK-Cu concerns topical, cosmetic application, such as facial or scalp creams and serums, rather than wound healing directly or systemic administration. Cross-species animal research, in dogs, rats, mice and pigs, has studied topical, subcutaneous and intraperitoneal wound-healing applications, but no controlled human wound-healing trial has been identified to date, and no controlled human data exists for injectable or systemic use. These are genuine evidence gaps, not incidental caveats: the topical-cosmetic and injectable-or-systemic uses of GHK-Cu sit under separate regulatory frameworks, detailed in the Regulatory Status section of this page.

Mechanisms and targets

Angiogenesis promotionAnti-inflammatoryAntioxidantExtracellular-matrix modulationGene-expression modulationCopper-transport/chelation-linked activity (no confirmed receptor)

Classification and structure

Names
GHK-Cu; Copper peptide GHK; Copper Tripeptide-1 (INCI cosmetic name); Glycyl-L-Histidyl-L-Lysine-Copper(II); GHK copper complex
Class
Copper-binding tripeptide (metallopeptide complex)
Origin
Endogenous
Structure
Gly-His-Lys (glycyl-L-histidyl-L-lysine), naturally chelates Cu2+ to form the GHK-Cu complex. First isolated from human plasma by Loren Pickart in 1973; also present in saliva and urine, declining with age.
Routes used in the research
Topical application (creams, serums) in the human trials reviewed. Animal wound-healing studies (dogs, rats, mice, pigs) used topical, subcutaneous and intraperitoneal routes. No human trial identified used injectable or systemic administration. This is a material evidence gap.How the substance was given in the studies cited on this page. This describes study methods only. It is not guidance on use.

What does the research show?

GHK-Cu has 6 recorded research findings. Each shows how strong it is, the kind of study behind it, its source and its main limitation.

Findings by strength of evidence

6 findings

Counts recorded findings by grade. It does not rate the compound.

Findings by strength of evidence
PreliminaryLimitedModerateStrongNot graded
33000

Fibrillin-1 deposition over six months Limited

A double-blind, randomised, vehicle-controlled cosmetic anti-ageing product trial reported measurable improvement in fibrillin-1 deposition (a marker of dermal matrix repair) over 6 months, with a non-significant trend toward clinical wrinkle improvement at 6 months that became apparent only after a further 6-month open extension.

Study type
Human trial
Population
60 adults with photoaged skin (30 test, 30 vehicle), face and hands, 6 months plus 6-month extension
Source
1 Watson et al., 2009

Limitation: Single RCT, not independently replicated; the full ingredient list of the tested product is not confirmed, so GHK-Cu's own contribution cannot be separated from the formulation.

Limitations in full

Single RCT, not independently replicated; the full ingredient list of the tested product is not confirmed, so GHK-Cu's own contribution cannot be separated from the formulation. The primary endpoint (wrinkle score) was not statistically significant at 6 months; only the fibrillin-1 biomarker and the extended-timepoint clinical read were positive.

Facial cream, 71 women Limited

A GHK-Cu-containing facial cream reduced visible signs of photoaging (laxity, wrinkle severity, skin density) over 12 weeks in a cohort of 71 women, per a narrative review's summary of the original trial.

Study type
Human trial
Population
71 women, 12 weeks, facial application
Source
2 Pickart et al., 2015

Limitation: Reported in a 2015 review (Pickart et al.), which cites a 2002 conference presentation.

Limitations in full

Reported in a 2015 review (Pickart et al.), which cites a 2002 conference presentation. The original trial was not published as a journal article.

GHK with 5-ALA, hair count Preliminary Combination, not GHK-Cu alone

A combination product containing GHK plus 5-aminolevulinic acid (5-ALA) increased hair count in patients with androgenetic alopecia over 6 months.

Study type
Human trial
Population
Androgenetic alopecia patients
Source
3 Lee et al.

Limitation: Combination product; GHK's independent contribution cannot be isolated from 5-ALA's; single study, not independently replicated.

Animal wound-closure models Limited

GHK-Cu accelerates wound closure and tissue repair across multiple animal species and tissue types (skin, hair follicles, gastrointestinal tract, bone, footpads) in preclinical models.

Study type
Animal
Population
Dogs, rats, mice, pigs (multiple studies, summarised in review)
Source
2 Pickart et al., 2015

Limitation: Well-established and cross-species, but no controlled human wound-healing trial exists in the sources reviewed; all human trial evidence located concerns cosmetic photoaging endpoints, not wound repair directly, a real evidence-type gap, not a minor caveat.

Human gene-expression arrays Preliminary

In gene-expression array studies, GHK is reported to up- or down-regulate several thousand human genes associated with tissue repair, inflammation and matrix regulation.

Study type
Lab (in-vitro)
Population
Human cell/tissue gene-array data (Pickart group)
Source
2 Pickart et al., 2015

Limitation: Purely mechanistic/array-level data; not independently replicated by a research group outside the original authors in the sources reviewed.

Registered topical gel trial Preliminary

A clinical trial of topical GHK-Cu gel for acute skin wound healing is currently registered.

Study type
Regulatory-clinical source
Population
Not yet reported (registry entry only)
Source
4 registered sponsor/investigator

Limitation: A registry entry documents that a trial exists/was designed; it is not evidence of an outcome until results are published.

What safety findings have been reported?

2 safety findings are recorded for GHK-Cu. A short list does not mean a substance is safe; it reflects what has been studied and reported.

Topical product, one trial, adverse events not reported in the abstract

The only human trial cited here tested a cosmetic anti-ageing product in 60 adults for 6 months, followed by a 6-month open phase. The published abstract does not report adverse events, and the full ingredient list of the product is not confirmed, so the effect of GHK-Cu itself cannot be separated out. A trial of 60 people is too few to rule out rarer harms. Nothing here applies to injection or other non-topical use.

Source
1 Watson et al., 2009

No injectable human safety data

No controlled human safety data for injectable or systemic GHK-Cu have been identified.

Source
2 Pickart et al., 2015

What is GHK-Cu's UK regulatory status?

Marketing authorisation
Topical/cosmetic use: not applicable; cosmetics do not receive medicinal marketing authorisation, they are regulated as cosmetic products, not medicines. Injectable/systemic use: none; no MHRA marketing authorisation exists for any GHK-Cu product intended for injectable or other systemic human administration.
Prescription status
Topical/cosmetic use: not applicable; sold over the counter as a cosmetic ingredient. Injectable/systemic use: not applicable; no licensed UK product was found to classify as prescription-only, pharmacy, or general sale.
Medicine class
Topical/cosmetic use: not classified as a medicine when marketed solely on cosmetic claims (for example, "improves the appearance of skin"), under the Cosmetic Products Enforcement Regulations 2013 (SI 2013/1478). Injectable/systemic use: would meet the Human Medicines Regulations 2012 (SI 2012/1916), Regulation 2 definition of a "medicinal product" if administered or marketed with a view to a pharmacological or physiological effect in humans, an unlicensed medicinal product in that context.
MHRA position
Topical/cosmetic use: not a medicinal product as currently marketed under cosmetic claims. MHRA's own borderline-classification test (Guidance Note 8) assesses products case by case on presentation and mechanism of action; a copper-peptide product would cross into medicinal-product territory if marketed with therapeutic claims (for example, "heals wounds", "treats a skin condition") rather than cosmetic-appearance claims. Injectable/systemic use: would be treated as an unlicensed medicinal product if supplied or marketed for administration to humans with a therapeutic purpose, under the Human Medicines Regulations 2012 general prohibition on marketing unauthorised medicines.
Authorised use
None on either track. Cosmetic claims only (appearance-related) on the topical track, never a treated medical indication; no approved indication anywhere for the injectable/systemic track.
Other restrictions
Topical/cosmetic use: must meet UK Cosmetic Products Regulation safety-assessment, notification and labelling requirements (INCI naming, safety assessor sign-off). Injectable/systemic use: see the general Human Medicines Regulations 2012 framework above.

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. GHK-Cu is recorded as not licensed in the UK (checked 14 August 2026).

References

5 sources, numbered as cited above. Each has its own page with its limitations and everything that cites it.

  1. Watson REB, et al. (2009). A cosmetic anti-ageing product improves photoaged skin: a double-blind, randomized controlled trial. British Journal of Dermatology, 161(2):419-426Human clinical trial, RCT · DOI 10.1111/j.1365-2133.2009.09216.x · PMID 19438432 · Original ↗
  2. Pickart L, Vasquez-Soltero JM, Margolina A (2015). GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International, 2015:648108DOI 10.1155/2015/648108 · PMID 26236730 · Original ↗
  3. Lee W, et al. Combination of 5-aminolevulinic acid and GHK peptide for androgenetic alopecia. Annals of DermatologyHuman clinical trial · PMID 27489425 · Original ↗
  4. registered sponsor/investigator Topical GHK-Cu Gel for Acute Skin Wound Healing (trial registry entry). ClinicalTrials.gov (NIH/NLM)Regulatory-clinical source · Original ↗
  5. MHRA (2026). Guidance Note 8: A guide to what is a medicinal product. GOV.UK / MHRARegulatory / legislative document · Original ↗

Questions about GHK-Cu

What is GHK-Cu?

GHK-Cu is a naturally occurring copper-binding tripeptide studied for skin ageing and wound healing. In the UK, topical products with cosmetic claims are regulated as cosmetics rather than medicines, no licensed injectable product exists, and the controlled human evidence concerns topical use only. Read what it is.

Is GHK-Cu licensed in the UK?

PeptGuru records GHK-Cu's UK status as: Not licensed in the UK. Topical/cosmetic use: not applicable; cosmetics do not receive medicinal marketing authorisation, they are regulated as cosmetic products, not medicines. UK status checked 14 August 2026. This is a record of regulation, not a recommendation. Read the UK status.

What does the research on GHK-Cu show?

PeptGuru records 6 research findings for GHK-Cu: 3 from human trials, 1 from an animal study, 1 from a lab (in-vitro) study and 1 from a regulatory or other record. Each finding has its own evidence grade, source and main limitation. Read the research findings.

What safety findings have been reported for GHK-Cu?

2 safety findings are recorded, including: topical product, one trial, adverse events not reported in the abstract; no injectable human safety data. Each is cited to its source. A short list does not mean a substance is safe. Read the safety findings.

Where are the sources for GHK-Cu?

All 5 sources are listed in the references, each with a link to the original study or regulator document and its own source page on PeptGuru. See the references.

Review record and change log

Last reviewed
Evidence last reviewed
UK status checked
Reviewed by
PeptGuru editorial team

How findings are graded: the grading method. All changes.

  • BPC-157Body Protection Compound-157

    Synthetic gastric-derived peptide studied in animal models of tissue healing. Not licensed in the UK; human evidence is one small uncontrolled study.

    Repair and regenerationHuman observationalEvidence reviewed
    LimitedNot licensed in the UK
  • TB-500Thymosin Beta-4 fragment

    Short synthetic fragment linked to thymosin beta-4. Not licensed in the UK. No human trials of TB-500 itself were found; trials of the full-length protein are not evidence for it.

    Repair and regenerationAnimal studiesEvidence reviewed
    LimitedNot licensed in the UK
  • Thymosin beta-4Thymosin β4

    Natural 43-amino-acid peptide studied in eye and wound-healing trials. Not licensed in the UK. Trials were small with mixed results. It is not TB-500.

    Repair and regenerationHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • EpithalonEpitalon

    Synthetic four-amino-acid peptide studied in ageing research. Not licensed in the UK; evidence is mostly laboratory and animal work from one group.

    Immune and longevityHuman trialsEvidence reviewed
    LimitedNot licensed in the UK

Compare GHK-Cu with BPC-157

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.